CIK 0001739174 · Non-accelerated filer<br>Smaller reporting company
Tessera Defense & Homeland Security Inc.
Sign in to watch- Ticker
- HLSQ
- Exchange
- NYSE
- Industry
- Services-Prepackaged Software
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 823364020
- Phone
- 972 545610935
- Business address
- 850 NEW BURTON ROAD, SUITE 201, DOVER, DE, 19904
- Former names
- BiomX Inc., Chardan Healthcare Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 32 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-15 | Flynn James E Director | Grant or award · Series X Non-Voting Convertible Preferred Stock | +13,490 | 13,490 | ||
| 2024-03-15 | Flynn James E Director | Grant or award · Series X Non-Voting Convertible Preferred Stock | +13,490 | 13,490 | ||
| 2024-03-15 | Flynn James E Director | Grant or award · Series X Non-Voting Convertible Preferred Stock | +40,350 | 53,840 | ||
| 2024-03-15 | Flynn James E Director | Grant or award · Series X Non-Voting Convertible Preferred Stock | +40,350 | 53,840 | ||
| 2024-03-15 | OrbiMed Israel BioFund GP Limited Partnership 10% owner | Purchase · Series X Preferred Stock | +4,327 | 4,327 | ||
| 2024-03-15 | OrbiMed Israel BioFund GP Limited Partnership 10% owner | Purchase · Warrants (Right to Buy) | +2,163,500 | 2,163,500 | ||
| 2023-12-11 | Wolfson Marina Chief Financial Officer | Returned to the company · Common Stock Options - Right to Buy | −36,000 | 0 | ||
| 2023-12-11 | Wolfson Marina Chief Financial Officer | Grant or award · Common Stock Options - Right to Buy | +9,474 | 9,474 | ||
| 2023-12-11 | Wolfson Marina Chief Financial Officer | Returned to the company · Common Stock Options - Right to Buy | −33,250 | 0 | ||
| 2023-12-11 | Wolfson Marina Chief Financial Officer | Grant or award · Common Stock Options - Right to Buy | +8,750 | 8,750 | ||
| 2023-12-11 | Wolfson Marina Chief Financial Officer | Returned to the company · Common Stock Options - Right to Buy | −50,000 | 0 | ||
| 2023-12-11 | Wolfson Marina Chief Financial Officer | Grant or award · Common Stock Options - Right to Buy | +35,715 | 35,715 | ||
| 2023-12-11 | Bassan Merav Chief Development Officer | Returned to the company · Common Stock Options - Right to Buy | −47,500 | 0 | ||
| 2023-12-11 | Bassan Merav Chief Development Officer | Grant or award · Common Stock Options - Right to Buy | +12,500 | 12,500 | ||
| 2023-12-11 | Bassan Merav Chief Development Officer | Returned to the company · Common Stock Options - Right to Buy | −100,000 | 0 | ||
| 2023-12-11 | Bassan Merav Chief Development Officer | Grant or award · Common Stock Options - Right to Buy | +71,429 | 71,429 | ||
| 2023-12-11 | Solomon Jonathan Eitan Chief Executive Officer | Returned to the company · Common Stock Options - Right to Buy | −144,000 | 0 | ||
| 2023-12-11 | Solomon Jonathan Eitan Chief Executive Officer | Grant or award · Common Stock Options - Right to Buy | +37,895 | 37,895 | ||
| 2023-12-11 | Solomon Jonathan Eitan Chief Executive Officer | Returned to the company · Common Stock Options - Right to Buy | −152,000 | 0 | ||
| 2023-12-11 | Solomon Jonathan Eitan Chief Executive Officer | Grant or award · Common Stock Options - Right to Buy | +40,000 | 40,000 |
Page 5 of 12 · 240 trades